NASDAQ$HCAT
Health Catalyst Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Health Catalyst's first quarter results for 2024 were reported, demonstrating strong financial performance with revenue of $74.7 million and Adjusted EBITDA of $3.4 million, exceeding the midpoint of quarterly guidance.
Health Catalyst reported a 1% increase in total revenue, reaching $74.7 million for the first quarter of 2024. The company's Adjusted EBITDA was $3.4 million. They are reiterating the full year 2024 total revenue and Adjusted EBITDA guidance ranges and also reiterating both of their bookings metrics, inclusive of dollar-based retention rate and net new DOS Subscription client additions.
- Total revenue for Q1 2024 was $74.7 million, a 1% increase year-over-year.
- Adjusted EBITDA for Q1 2024 was $3.4 million.
- The company is reiterating its full-year 2024 revenue guidance of $304.0 million to $312.0 million.
- The company is reiterating its full-year 2024 Adjusted EBITDA guidance of $24.0 million to $26.0 million.
Headline financials
Revenue & EPS history
Health Catalyst · Revenue · Quarterly
$74.7M
Revenue by segment
Health Catalyst · $73.8M total across 2 segments · Q3 2023
- Technology$46M+4.5%62.3%
- Professional Services$27.8M+14.1%37.7%
Forward guidance
Health Catalyst provides forward-looking guidance on total revenue and Adjusted EBITDA. For the second quarter of 2024, the company expects total revenue between $73.5 million and $76.5 million, and Adjusted EBITDA between $5.0 million and $7.0 million. For the full year 2024, the company expects total revenue between $304.0 million and $312.0 million, and Adjusted EBITDA between $24.0 million and $26.0 million.
Tailwinds
- Total revenue guidance for Q2 2024 is between $73.5 million and $76.5 million.
- Adjusted EBITDA guidance for Q2 2024 is between $5.0 million and $7.0 million.
- Total revenue guidance for the full year 2024 is between $304.0 million and $312.0 million.
- Adjusted EBITDA guidance for the full year 2024 is between $24.0 million and $26.0 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2024
-3.1%
Avg return
Earnings day
-3.9%
Avg return
5 days after
-4.0%
Avg return
30 days after
41%
11 / 27 earnings
Positive
+27.3%
Q2 2024
Best reaction
-36.6%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -9.9% | -21.7% | +4.6% | |
| Q4 2025 | -26.3% | -35.2% | -44.4% | |
| Q3 2025 | -5.6% | -20.5% | -10.2% | |
| Q1 2025 | +5.3% | +8.1% | +3.3% | |
| Q4 2024 | -11.1% | -8.5% | -7.9% | |
| Q3 2024 | +14.2% | +7.2% | +7.6% | |
| Q2 2024 | +27.3% | +7.3% | +22.9% | |
| Q1 2024 | -3.6% | +2.9% | -2.3% | |
| Q4 2023 | -14.7% | -8.9% | -14.4% | |
| Q3 2023 | +5.1% | -0.4% | +5.3% | |
| Q2 2023 | -8.0% | -5.0% | -12.4% | |
| Q1 2023 | -18.9% | -14.8% | -4.3% | |
| Q4 2022 | +7.3% | +5.8% | -14.8% | |
| Q3 2022 | +16.2% | +42.9% | +59.2% | |
| Q2 2022 | -36.6% | -34.7% | -35.9% | |
| Q1 2022 | -2.6% | +24.6% | +10.5% | |
| Q4 2021 | +1.5% | -7.1% | -3.7% | |
| Q3 2021 | -6.2% | -6.1% | -26.9% | |
| Q2 2021 | +1.5% | -2.3% | -2.8% | |
| Q1 2021 | -2.3% | -8.6% | -2.4% | |
| Q4 2020 | +0.6% | +0.1% | -2.1% | |
| Q3 2020 | -0.2% | -3.5% | +6.2% | |
| Q2 2020 | -7.2% | -10.9% | -3.4% | |
| Q1 2020 | -1.9% | -0.5% | -5.0% | |
| Q4 2019 | +1.3% | -5.8% | -20.1% | |
| Q3 2019 | +1.9% | -0.8% | -1.1% | |
| Q2 2019 | -11.5% | -7.8% | -13.1% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro